EGFR-IN-42

EGFR-IN-42 (Compound 17b) is a potent, dual-action inhibitor that covalently combines gefitinib with tamoxifen pharmacophores. This hybrid molecule exhibits single-digit nanomolar EGFR inhibition while maintaining estrogen receptor antagonism, leading to enhanced anti-proliferative activity in cancer cell studies. Its design is relevant for investigating combination therapies in EGFR-driven and ER-positive cancers.